Wave Life Sciences’ share price has been in the doldrums since late 2019, when its Duchenne muscular dystrophy project suvodirsen crashed, followed by disappointing data with one of its Huntington’s disease assets, WVE-120102.

The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.

Data from a phase 1b/2a trial have raised doubts about whether Wave Life Sciences’ Huntington’s disease drug can compete with Roche and Ionis’ rival candidate. The results wiped 50% off Wave’s share price, adding to losses it suffered when it dumped a Duchenne muscular dystrophy (DMD) program earlier in December.